DAX-1,71 % EUR/USD-0,03 % Gold+0,33 % Öl (Brent)+0,84 %

News around the world (Seite 2703)

Begriffe und/oder Benutzer


AFC Energy - Air Products joins Power Up project Trading +Operational Update, "aim of the project is to generate electricity using surplus hydrogen produced from a chemical plant, using one of the world's largest alkaline fuel cell power systems" - Nov 6, 2013
22 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
President Energy Plc - " "eyes" 500.000.000 Barrels, in Paraguay" - Nov 4, 2013
3 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
"Five years from now every pharma "will" have a nano program"; While there are 49 products on the market incorporating nanoparticles, there are four times that many now moving through the Pipeline, with half of those already in PhaseII or PhaseIII trials. In his role as vice chair for the European Technology Platform on Nanomedicine, Laurent Levy described the state of the emerging field of nanotherapeutics to set the context for a special workshop @BIO-Europe® 2013 asking, "Is nano becoming the next sweet spot for drug development?" – N/Partnering360 – Nov 12, 2013
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Argex Titanium - Commences Equipment Ordering Process, For Valleyfield Plant - Nov 25, 2013

+ Vendors have commenced preliminary engineering for the longest lead items

+ Delivery-time on other items have been reduced materially

+ Argex "focused on 2015 production +revenue"

"MONTREAL, Nov. 25, 2013 /CNW Telbec/ - Argex Titanium Inc. (TSX: RGX) ("Argex" or the "Company") announced today that it has commenced preliminary engineering work with the equipment vendors for the longest lead items as the first step in the ordering of the equipment for the Valleyfield industrial-sized plant.

"This is an important step in the equipment ordering process," commented Enrico Di Cesare, Argex's Chief Operating Officer and Vice-President of Technology, "it effectively maintains our company's planned schedule by securing our priority with the vendors for delivery."

"Furthermore, other equipment items that we had previously identified as having some of the longest lead times have been recategorized based on updated vendor information," commented Mr. Di Cesare, "the ongoing testing work that we have been carrying-out with many of the equipment vendors have led to their improved understanding of our requirements and this has led to materially reduced delivery times. In some cases, weaker market conditions for required equipment have also improved the delivery times and prices previously expected."

"Our core strategy at Argex continues to be to mitigate risk while moving rapidly towards 2015 production and revenue," he added, "the next steps will be the finalization of the purchase orders for the long lead items and the selection of the remaining equipment in the first quarter of 2014."

About Argex Titanium Inc.

ARGEX Titanium Inc. is a near-term producer of Titanium Dioxide (TiO2) pigment. With a primary goal of advancing rapidly towards production, Argex has adopted a simple and low-risk strategy for the scale-up of its proprietary process. Argex is pleased to have selected Valleyfield, Quebec as the location for its Research & Development centre and first industrial-sized production facility. The location of the site can be viewed at Argex Valleyfield. "
Antwort auf Beitrag Nr.: 45.915.046 von Popeye82 am 25.11.13 18:23:14
Nanobiotix "bidding to revolutionise radiotherapy, with Technology" - PAIUK - Oct 28, 2013

- I. Lyall -

"The last decade has seen the development of nanotechnology with varying degrees of success in manufacturing, materials and coatings.

But few, if any, of the innovations that have come via this route could lay claim to having the life-enhancing potential of the platform created by Nanobiotix.

For the Euronext-listed company believes its discovery, spun out of the University of Buffalo, New York, will revolutionise radiotherapy, which is used to treat 60% of cancer patients, or six million people annually.

While it may be administered like a traditional drug, you should actually consider Nanobiotix’s NanoXray technology as just that – a technology.

It should rank alongside the scalpel, the syringe and the MRI scanner as a tool used by a doctor and that has a physical interaction with the body, rather than a chemical or biological effect, says chief executive Laurent Levy.

The distinction will become apparent later – and it creates a far bigger opportunity for the product and for investors than a traditional small or large molecule treatment might.

The NanoXray is as elegantly simple in concept as it is difficult to explain.

Tiny particles of hafnium oxide are injected directly to the tumour, administered intravenously or applied as a gel during surgery to give a targeted treatment.

This non-toxic material is there to absorb x-rays as well as enhance the dose of radiotherapy. It increases the dose in the tumour without increasing the dose in healthy tissues.

It is important to stress, while the NanoXray can be administered like a medicine and its particles are so tiny thousands can fit around the circumference of a hair, the reaction is physical rather than chemical or biological.

What does this mean? Well, it creates a one-size-fits-all approach to treatment that you just don’t have with conventional medicine.

“You develop a drug and you have a number of risks as you never know how the drug will interact with [human] biology,” explains chief executive Levy.

“We are using physics [to shrink tumours] and with physics you know it is going to work. If you heat a cell to 80 degrees you know you are going to kill them no matter about the genetics from one patient to the other.”

The injection method of administering the nanoparticles is being piloted in soft tissue sarcoma (STS), head and neck cancer and liver cancer (with the latter supported by a €2.8mln grant from bpifrance).

The gel and intravenous indications are still in the pre-clinical phase.

Even so, the company has a huge marketplace to aim for having achieved proof of concept with direct injection in STS.

Meanwhile, the time line and costs associated with getting this nanomedicine to market are far shorter and cheaper than you’d see in traditional drug development.

Levy expects the NanoXray technology to be tested on 200-300 cancer patients to demonstrate its benefits, rather than the 1,000 that might be seen in a traditional drug trial.

“We are surfing on an existing market. What we need to show is compared with radiotherapy alone we have a significant benefit,” says Levy. “This is how we are working on our clinical trial.”

As expected, the company will require additional funds to get the NanoXray to market in Europe, where it will go through the CE Mark process.

Yet the addressable market is huge – with an estimated one million patients in the world’s seven most developed economies amenable to the treatment and another one million in the BRIC countries.

An extensive period of marketing to assess what the users of such a breakthrough treatment would pay will give a better assessment of the exact scale of the market.

However, Philippe Mauberna, Nanobiotix’s chief financial officer, reckons the first product for the treatment, due on the market in 2017 in Europe, might generate around €1bn a year.

Here, the company hopes to take the NanoXray platform all the way through the approval process, while finding an additional partner to help it develop and commercialise the invention outside the European markets.

In Asia it has partnered with PharmaEngine in a deal worth around US$57mln in milestone and other payments.

Meanwhile, Nanobiotix is looking for a group to help it crack the all-important US market.

Stateside it is likely to seek out a traditional pharma company with a large oncology franchise, or one looking to make a splash in this arena, Levy reveals.

However it plays out, Levy is confident Nanobiotix has created a unique technology.

“We have developed a powerful tool that could destroy cancer cells, in a broad number of patients, and this is a key difference [to traditional medicine]” says Levy.

“This disruptive technology is the value proposition we have to put.”


Nanobiotix, pioneer and leader in nanomedicine has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and maximize the effect of radiotherapy within tumor cells. NanoXray products enhance the radiotherapy efficacy in the tumor without increasing healthy tissues damages. NanoXray products are built on the existing standard of care and can be used with every existing radiation equipment available in almost every hospital world-wide. "

Eagle Star Minerals - Drills High-Grade Phosphate, @Former Vale Property, +"Confirms Extension of MbAC's Deposit" - Nov 25, 2013
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Apple buys Israeli 3D sensor outfit PrimeSense for a reported $350.000.000; The deal gives Apple proven technology (it powers Microsoft’s Kinect controllers) that could be used in a wide range of contexts. - GO - Nov 25, 2013

- David Meyer -

"Apple has bought an Israeli motion control company called PrimeSense, in a deal that’s been rumored for over 4 months now. PrimeSense makes 3D sensors, and has until now been best known for powering Microsoft’s Kinect controller for the Xbox and PCs.

PrimeSense’s most popular product is a multi-sense (depth, color and audio) recognition system-on-a-chip called Carmine, and the successor to that, Capri, is described as having “improved algorithms including multi-modal 3D sensing techniques, that enable superior performance resolutions, smaller form factor, and cost reduction.”

What does Apple want with such technology? It could find applications in a variety of contexts, from Apple TV to — miniaturization permitting — the iPad and the company’s fabled entry into the world of wearable computing. PrimeSense’s advanced depth perception tech could theoretically even be used to turn future iPhones into handheld 3D scanners.

Apple confirmed the buy to AllThingsD on Sunday, and a PrimeSense spokeswoman confirmed it again on Monday morning, but refused to give further details.

A report by the Israeli publication Calcalist earlier in November pegged the deal at a value of $345 million. An unnamed source told Bloomberg early Monday that the price was “about” $350 million. "
"Let’s build a semantic web by creating a Wikipedia for relevancy"; The relevancy-defining, edge-weighting algorithms of Google’s Knowledge Graph, Facebook’s Open Graph +Gravity’s Interest Ontology are closely guarded company secrets. "Imagine if that data was available to everyone — it would be as disruptive as Amazon Web Services. The internet would be a better place" - GO - Nov 25, 2013

- Jim Benedetto -
Seedrs becomes first equity crowdfunding platform to operate across Europe; The British platform will have some immediate advantages over many local rivals as it leaps across the English Channel, namely continent-wide scale +a higher funding limit than that available in some mainland European countries - GO - Nov 25, 2013

- David Meyer -

"The British crowdfunding platform Seedrs, which offers investors equity rather than “perks”, has become the first of its kind to open shop across Europe.

Seedrs officially began its UK operations in July last year. The firm is unusual in that it holds the shares in the startups crowdfunded through its platform, on the investors’ behalf as a nominee. According to CEO Jeff Lynn (pictured), this makes life much easier for the startups when they want to raise venture funding in the future, as VCs aren’t crazy keen on companies that have hundreds of early-stage investors – try getting all those people to sign the necessary paperwork, for a start.

Now Seedrs is going Europe-wide, taking on a range of rivals across different countries such as Seedmatch in Germany. Of course, operating across the continent gives Seedrs something of an edge when it comes to scale.

“A platform like ours is a network effects-driven platform,” Lynn told me. “The more investors we have, the more value we create for entrepreneurs. The more deal flow we have, the more value we create for investors. National borders are kind of arbitrary when it comes to investing and startups – offline, people tended to invest close to home, but on the internet why would you limit it to just one country?”

Scale isn’t the only advantage, though. Under European law, EU member states can allow the raising of up to €5 million ($6.8 million) through equity crowdfunding platforms – but they can also set the limit as low as €100,000, which many such as France still do. The UK set its cap at €5 million and, as that’s where Seedrs is based, that’s its limit across the EU.

“The individual country rules aren’t the ones that apply in our case – everything we do is under UK law,” Lynn said. “It gives us a huge advantage.”

Seedrs said on Monday that it now has more than 25,000 registered investors, and that it has funded 48 early-stage deals since it opened shop. In a case of crowdfunding Inception, Seedrs also said it would be raising £500,000 ($810,000) for itself, using itself, offering an 8.81 percent equity stake (presumably to be held by itself as the nominee) in return.

This article was updated at 2.20am PT to excise Seedrs’ claim that it was the first equity crowdfunding platform to operate across borders. A Swedish platform called FundedByMe is already operating in 7 European markets, though not all of them. "
Gemini - Executes Multi-Year Alliance, with "one of the world’s largest module fabricators" - Nov 25, 2013

Beitrag zu dieser Diskussion schreiben